A LinkedIn post from Andelyn Biosciences highlights the company’s use of NanoMosaic Inc.’s Tessie platform for high‑resolution adeno‑associated virus, or AAV, vector characterization. The post notes that this advanced analytics technology has received the U.S. FDA’s Advanced Manufacturing Technology designation, and points readers to a blog discussing how next‑generation tools may improve data quality and accelerate gene therapy development timelines.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
For investors, the focus on high‑resolution AAV analytics suggests Andelyn is investing in process robustness and regulatory‑aligned manufacturing capabilities in the cell and gene therapy space. Adoption of FDA‑recognized advanced manufacturing platforms could enhance the company’s competitiveness as a contract development and manufacturing partner, potentially supporting higher‑value collaborations, improved development efficiency, and better positioning as regulatory expectations for gene therapy quality and characterization continue to rise.